Clinical trial · Observational
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
UCSF Biobank for Studying Hereditary Cancers and Tumor-Associated Mutations
NCT06895681CI-TRIAL-00125297withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): IRB study closure
Summary
Brief summary (as posted)
This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hereditary Cancer | Hereditary Malignant Neoplasm | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
| Somatic Mutation | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sample | Procedure | — | UNRESOLVED |
| Excess fluid Sample | Procedure | — | UNRESOLVED |
| Medical Chart Review | Other | — | UNRESOLVED |
| Tissue Sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adults with solid tumor malignancies
- description
- Participants' biospecimen samples (Tissue, Excess fluid (i.e., ascites, pleural effusions, and Blood) will be obtained during non-study, routine medical visits whenever possible, to minimize participant risk. Blood samples will be collected up to 5 times from consenting participants.
- interventionNames
- Procedure: Blood Sample
- Procedure: Tissue Sample
- Procedure: Excess fluid Sample
- Other: Medical Chart Review
Primary outcomes (1)
- measure
- Develop participant-derived tumor models of hereditary cancers
- timeFrame
- Up to 10 years
- description
- Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). These models recapitulate the biology and tissue context of the original tumors from which they are derived and can be used to study effective therapeutic strategies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For participants undergoing collection of tissue, ascites, and/or pleural effusions: 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted. 2. Individuals 18 years of age or older on the day of signing informed consent. 3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer. 4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol): 1. Surgical resection 2. Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted) 3. Paracentesis 4. Thoracentesis For participants undergoing blood banking: 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted. 2. Individuals 18 years of age or older on the day of signing informed consent. 3. Individuals with a family history or personal history of cancer. 4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care. Exclusion Criteria: 1\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.
References
Publications (0)
Data not yet available
No reference posted for this study.